Total Payments
$54,301
2024 Payments
$13.87
Companies
33
Transactions
161
Medicare Patients
953
Medicare Billing
$119,564
Payment Breakdown by Category
Other$22,930 (42.2%)
Consulting$19,050 (35.1%)
Travel$6,157 (11.3%)
Food & Beverage$4,204 (7.7%)
Research$1,954 (3.6%)
Education$5.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $22,930 | 11 | 42.2% |
| Consulting Fee | $19,050 | 6 | 35.1% |
| Travel and Lodging | $6,157 | 23 | 11.3% |
| Food and Beverage | $4,204 | 116 | 7.7% |
| Unspecified | $1,954 | 4 | 3.6% |
| Education | $5.00 | 1 | 0.0% |
Payments by Type
General
$52,347
157 transactions
Research
$1,954
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $20,112 | 26 | $0 (2018) |
| Lilly USA, LLC | $18,511 | 23 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $11,793 | 23 | $0 (2020) |
| Eli Lilly and Company | $1,746 | 6 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $576.24 | 21 | $0 (2021) |
| Clovis Oncology, Inc. | $257.02 | 3 | $0 (2018) |
| Genentech USA, Inc. | $148.66 | 12 | $0 (2019) |
| Takeda Pharmaceuticals U.S.A., Inc. | $136.34 | 3 | $0 (2020) |
| GlaxoSmithKline, LLC. | $104.57 | 1 | $0 (2017) |
| Amgen Inc. | $89.39 | 5 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $13.87 | 1 | Amgen Inc. ($13.87) |
| 2023 | $27.02 | 1 | Pharmacyclics LLC, An AbbVie Company ($27.02) |
| 2022 | $135.06 | 2 | Novocure Inc. ($78.11) |
| 2021 | $116.41 | 1 | AstraZeneca Pharmaceuticals LP ($116.41) |
| 2020 | $454.46 | 21 | Takeda Pharmaceuticals U.S.A., Inc. ($92.13) |
| 2019 | $309.32 | 16 | AstraZeneca Pharmaceuticals LP ($46.21) |
| 2018 | $10,926 | 20 | Lilly USA, LLC ($5,962) |
| 2017 | $42,319 | 99 | PFIZER INC. ($16,895) |
All Payment Transactions
161 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/26/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $13.87 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/06/2023 | Pharmacyclics LLC, An AbbVie Company | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $27.02 | General |
| Category: ONCOLOGY | ||||||
| 10/14/2022 | Novocure Inc. | Optune (Device) | Food and Beverage | Cash or cash equivalent | $78.11 | General |
| Category: Oncology | ||||||
| 02/23/2022 | Myriad Genetic Laboratories, Inc. | myRisk (Device) | Food and Beverage | Cash or cash equivalent | $56.95 | General |
| Category: Germline DNA Sequencing Hereditary Cancer and Rearrangement Analysis | ||||||
| 10/13/2021 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $116.41 | General |
| Category: Oncology | ||||||
| 02/28/2020 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug), TAFINLAR, VOTRIENT | Food and Beverage | In-kind items and services | $14.00 | General |
| Category: ONCOLOGY | ||||||
| 02/27/2020 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $19.76 | General |
| Category: Oncology | ||||||
| 02/26/2020 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Food and Beverage | In-kind items and services | $18.31 | General |
| Category: Oncology | ||||||
| 02/19/2020 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $92.13 | General |
| Category: ONCOLOGY | ||||||
| 02/19/2020 | GENZYME CORPORATION | CABLIVI (Biological) | Food and Beverage | In-kind items and services | $18.47 | General |
| Category: Hematology | ||||||
| 02/10/2020 | Agios Pharmaceuticals, Inc. | TIBSOVO (Drug), IDHIFA | Food and Beverage | Cash or cash equivalent | $15.12 | General |
| Category: Oncology | ||||||
| 02/06/2020 | TOLMAR Pharmaceuticals, Inc. | ELIGARD (Drug) | Food and Beverage | In-kind items and services | $15.16 | General |
| Category: Prostate Cancer | ||||||
| 02/04/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $19.03 | General |
| Category: Oncology | ||||||
| 01/31/2020 | Boehringer Ingelheim Pharmaceuticals, Inc. | GILOTRIF (Drug) | Food and Beverage | In-kind items and services | $20.93 | General |
| Category: ONCOLOGY | ||||||
| 01/31/2020 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Food and Beverage | In-kind items and services | $17.12 | General |
| Category: Oncology | ||||||
| 01/27/2020 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $23.54 | General |
| Category: Oncology | ||||||
| 01/25/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $16.48 | General |
| Category: Oncology | ||||||
| 01/23/2020 | EMD Serono, Inc. | Bavencio (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: Oncology | ||||||
| 01/22/2020 | Astellas Pharma US Inc | XOSPATA (Drug) | Food and Beverage | In-kind items and services | $24.28 | General |
| Category: ONCOLOGY | ||||||
| 01/21/2020 | Rigel Pharmaceuticals, Inc. | Tavalisse (Drug) | Food and Beverage | In-kind items and services | $22.51 | General |
| Category: Hematology | ||||||
| 01/16/2020 | GENZYME CORPORATION | CABLIVI (Biological) | Food and Beverage | In-kind items and services | $19.36 | General |
| Category: Hematology | ||||||
| 01/14/2020 | Celgene Corporation | INREBIC (Drug) | Food and Beverage | Cash or cash equivalent | $20.00 | General |
| Category: Hematology | ||||||
| 01/13/2020 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $20.74 | General |
| Category: Oncology | ||||||
| 01/08/2020 | Secura Bio, Inc. | Farydak (Drug) | Food and Beverage | Cash or cash equivalent | $13.21 | General |
| Category: Oral Oncologic | ||||||
| 01/08/2020 | Secura Bio, Inc. | Farydak (Drug) | Food and Beverage | Cash or cash equivalent | $0.35 | General |
| Category: Oral Oncologic | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $993.78 | 2 |
| NEOMONARCH - A PHASE 2 NEOADJUVANT TRIAL COMPARING THE BIOLOGICAL EFFECTS OF 2 WEEKS OF ABEMACICLIB -LY2835219- IN COMBINATION WITH ANASTROZOLE TO THOSE OF ABEMACICLIB MONOTHERAPY AND ANASTROZOLE MONOTHERAPY AND EVALUATING THE CLINICAL ACTIVITY AND SAFETY OF A SUBSEQUENT 14 WEEKS OF THERAPY WITH ABEMACICLIB IN COMBINATION WITH ANASTROZOLE IN POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE, HER2 NEGATIVE BREAST CANCER | Eli Lilly and Company | $856.00 | 1 |
| A phase I II dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with fulvestrant in subjects with ER breast cancer | GlaxoSmithKline, LLC. | $104.57 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 232 | 360 | $150,392 | $28,497 |
| 2022 | 7 | 506 | 743 | $140,510 | $62,918 |
| 2021 | 5 | 203 | 297 | $55,712 | $26,467 |
| 2020 | 1 | 12 | 18 | $8,449 | $1,682 |
Total Patients
953
Total Services
1,418
Medicare Billing
$119,564
Procedure Codes
17
All Medicare Procedures & Services
17 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 134 | 249 | $98,105 | $18,278 | 18.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 46 | 58 | $31,917 | $6,455 | 20.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 24 | 24 | $12,609 | $2,527 | 20.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 28 | 29 | $7,761 | $1,236 | 15.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 114 | 114 | $41,400 | $17,531 | 42.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 129 | 222 | $39,072 | $17,464 | 44.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 103 | 140 | $33,124 | $16,834 | 50.8% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2022 | 66 | 153 | $9,462 | $4,135 | 43.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 62 | 73 | $9,470 | $4,007 | 42.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 20 | 29 | $4,642 | $1,723 | 37.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 12 | 12 | $3,340 | $1,223 | 36.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 52 | 72 | $17,210 | $8,813 | 51.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 49 | 90 | $15,120 | $7,540 | 49.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 44 | 44 | $16,058 | $6,900 | 43.0% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2021 | 40 | 66 | $4,356 | $1,793 | 41.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 18 | 25 | $2,968 | $1,421 | 47.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 12 | 18 | $8,449 | $1,682 | 19.9% |
About Dr. Elizabeth Tan-Chiu, M.D
Dr. Elizabeth Tan-Chiu, M.D is a Specialist healthcare provider based in Tampa, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1538113931.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Elizabeth Tan-Chiu, M.D has received a total of $54,301 in payments from pharmaceutical and medical device companies, with $13.87 received in 2024. These payments were reported across 161 transactions from 33 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($22,930).
As a Medicare-enrolled provider, Tan-Chiu has provided services to 953 Medicare beneficiaries, totaling 1,418 services with total Medicare billing of $119,564. Data is available for 4 years (2020–2023), covering 17 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Other Specialties Hematology & Oncology
- Location Tampa, FL
- Active Since 05/20/2006
- Last Updated 06/18/2025
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1538113931
Products in Payments
- IBRANCE (Drug) $15,602
- KISQALI (Drug) $11,618
- VERZENIO (Drug) $5,417
- RETACRIT (Biological) $3,200
- LYNPARZA (Drug) $321.62
- Rubraca (Drug) $257.02
- TAGRISSO (Drug) $116.41
- Perjeta (Biological) $101.03
- NINLARO (Drug) $92.13
- Optune (Device) $78.11
- IMFINZI (Drug) $73.74
- Prolia (Biological) $61.47
- myRisk (Device) $56.95
- FASLODEX (Drug) $42.03
- Lenvima (Drug) $41.84
- GILOTRIF (Drug) $38.09
- CABLIVI (Biological) $37.83
- KEYTRUDA (Biological) $37.77
- OPDIVO (Biological) $35.51
- EPKINLY (Drug) $27.02
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Tampa
Dr. Elliot Cazes, M.d, M.D
Specialist — Payments: $753,247
Specialist $753,247
Dr. George Letson, M.d, M.D
Specialist — Payments: $444,034
Specialist $444,034
Dr. Matthew Berlet, M.d, M.D
Specialist — Payments: $137,367
Specialist $137,367
Jose Ferreira, Md, MD
Specialist — Payments: $132,962
Specialist $132,962
Dr. Nirav Patel, M.d, M.D
Specialist — Payments: $104,346
Specialist $104,346
Dr. Ricardo Costa, Md, MD
Specialist — Payments: $83,311
Specialist $83,311